Navigation Links
Royalty Pharma Recommends Elan Shareholders vote "NO" on each of the Elan Resolutions at the Elan extraordinary general meeting
Date:5/29/2013

of the Irish Takeover Rules, all "dealings" in "relevant securities" of Elan by Elan or Royalty Pharma, or by any of their respective "associates" must also be disclosed by no later than 12 noon (Irish time) on the "business day" following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant securities" "dealings" should be disclosed can be found on the Irish Takeover Panel's website at www.irishtakeoverpanel.ie.

"Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of securities, or by virtue of any option in respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Irish Takeover Rules, which can be found on the Irish Takeover Panel's website.

If you are in any doubt as to whether or not you are required to disclose a "dealing" under Rule 8, please consult the Irish Takeover Panel's website at www.irishtakeoverpanel.ie or contact the Irish Takeover Panel on telephone number +353 (0)1 678 9020; fax number +353 (0)1 678 9289.

No Profit Forecast / Asset Valuations

No statement in this announcement constitutes a profit forecast for any period, nor should any statement be interpreted to mean that earnings or earnings per share will necessarily be greater or lesser than those for the relevant preceding financial periods for Royalty Pharma, RP Management or Elan as appropriate. No statement in this announcement constitutes an asset valuation.  


  


'/>"/>
SOURCE Royalty Pharma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Royalty Rates Take Center Stage in Biopharma Dealmaking
2. Royalty Pharma Announces Proposal To Acquire Elan
3. PDL BioPharma Provides First Quarter 2013 Royalty Revenue Guidance of $92 Million
4. Royalty Rates for Pharmaceuticals & Biotechnology: Real-Deal Information for Hundreds of Transactions
5. PDL BioPharma Completes Structured Financing and Royalty Transaction with Avinger
6. Selexis SA Sells Rights to Royalty Payments for More Than 15 Biologic Development Programs to Ligand Pharmaceuticals
7. Royalty Pharma Increases Offer for Elan to $12.50 Per Share in All Cash
8. Royalty Pharma Reduces Acceptance Condition to 50% Plus One Share
9. Royalty Pharma Discloses Acceptance Levels of Original Offer for Elan Pursuant to Irish and United States Regulatory Requirements
10. Royalty Pharma Issues Investor Presentation Highlighting The Strategic And Financial Advantages Of Its Offer To Acquire Elan For $12.50 Per Share In Cash
11. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Increase in R&D activities ... in Germany through 2020   ... report, " Germany Bioinformatics Market Forecast & Opportunities, 2020 ... is projected to register a CAGR of over 29% ... growth on account of rising government funding and initiatives, ...
(Date:7/6/2015)... -- Cardinal Health today announced the completion of the ... generic pharmaceuticals, over-the-counter medications and related products to retail, ... Court Square Capital Partners. The $1.115 billion acquisition was ... Headquartered in Livonia, Mich. ... approximately $450 million in 2014. There are 450 employees ...
(Date:7/6/2015)... , June 29, 2015 ... addition of the "Pharmaceutical Grade Sodium Chloride Market ... to 2019" report to their offering. ... witness a CAGR of 6.9% between 2014 and 2019 ... to reach 690 KT by 2019. The ...
Breaking Medicine Technology:Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 2Germany Bioinformatics Market to Grow at a CAGR Over 29% Through 2020 Says TechSci Research 3Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3Global Pharmaceutical Grade Sodium Chloride Market Report 2015 2Global Pharmaceutical Grade Sodium Chloride Market Report 2015 3
... Dec. 5, 2011 The National Foundation for Infectious ... Prevention (CDC) in highlighting the importance of influenza prevention ... 10, and encouraging vaccination through the holiday season and ... steadily increased over the past few years, but many ...
... TRAB), a manufacturer and distributor of homeopathic nasal sprays for ... and migraine headaches, today announced the relocation of its corporate ... located at 4400 Route 9 South in Manalapan, New Jersey ... for the Company,s future growth. Kelly Hickel, ...
Cached Medicine Technology:National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 2National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 3National Foundation for Infectious Diseases Supports 2011 National Influenza Vaccination Week 4TheraBiogen, Inc. Relocates Corporate Headquarters to New Jersey 2
(Date:7/7/2015)... ... July 07, 2015 , ... ... launch of their new website, the Invokana Ketoacidosis Lawsuit Center . The ... serves as a resource for persons wishing to learn more about Invokana lawsuits ...
(Date:7/7/2015)... ... July 07, 2015 , ... CareSync proudly announces ... recognized by the White House as a “Champion of Change” for Precision Medicine ... Initiative, the Champions of Change program recognizes Gleason and eight other extraordinary individuals ...
(Date:7/6/2015)... ... July 07, 2015 , ... Currently, mobile testing ... of AIDS, advances in the molecular diagnostic technologies, wide availability of immunosuppressive drugs ... detection technologies and genetic engineering also open lucrative opportunities for the market players. ...
(Date:7/6/2015)... ... ... TapGlance ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... rooms will look like before they even start renovating.. , Whether a person is ...
(Date:7/6/2015)... ... 2015 , ... Shortly after opening her second practice in Signal Hill, Dr. ... on a lien basis. Dr. Lim had previously worked with Dr. Kevin Kelly, ... refugees, Dr. Lim suffered with back pain herself throughout high school. Unaware of ...
Breaking Medicine News(10 mins):Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 2Health News:National Attorneys Launch Invokana Ketoacidosis Lawsuit Center 3Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 2Health News:White House names Champions of Change for Precision Medicine: CareSync COO Recognized 3Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Create a Space with TapGlance, a Revolutionary Interior Design Application 2Health News:Respected Chiropractor Opens Office in Signal Hill/Cambodia Town and Joins Doctors on Liens 2
... Statistical Significance, IRVINE, Calif., Oct. 30 ... Biotech, today,announced that the Phase 3 SPARC trial ... did not meet its primary,efficacy endpoint. "We ... for,satraplatin did not achieve statistical significance. Drug development ...
... of radiotherapy to treat breast cancer may, in some ... potentially toxic radiation as does the standard six weeks ... That because the short treatment, known as partial breast ... breast through multiple beams, these beams can pass through ...
... SGXP ) announced today that the company will ... Grey, president & chief,executive officer of SGX Pharmaceuticals, will ... conference information is as,follows: -- BIOCOM Investor Conference ... at 9:00 AM Pacific Daylight Time at the Marriott ...
... On Sunday, November 4,2007, Eli Lilly and Company ... with,the investment community and media to review the details ... Association,Scientific Sessions in Orlando, Florida. This call will follow ... TRITON TIMI-38 trial. The Lilly conference call will ...
... Higher Volumes, ALISO VIEJO, Calif., Oct. 30 ... technology and services resource for,pathologists, oncologists and the ... quarter ended September 30, 2007. Revenue,from continuing operations ... 2007,an increase of 52 percent compared to $7.9 ...
... 2007 4:30 p.m. EST http://www.nucryst.com , WAKEFIELD, ... a webcast at 4:30 p.m. EST on Wednesday, November ... In addition to standard disclosure over wire services, a ... NUCRYST web site. To listen,to the call live on ...
Cached Medicine News:Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 2Health News:GPC Biotech Today Announced Results of Survival Analysis from the SPARC Trial 3Health News:Normal tissue not spared in new forms of breast cancer radiotherapy 2Health News:SGX Pharmaceuticals to Present at Three Upcoming Investor Conferences 2Health News:Clarient Generates 52% Revenue Increase in Third Quarter 2007 2Health News:Clarient Generates 52% Revenue Increase in Third Quarter 2007 3Health News:Clarient Generates 52% Revenue Increase in Third Quarter 2007 4Health News:Clarient Generates 52% Revenue Increase in Third Quarter 2007 5Health News:Clarient Generates 52% Revenue Increase in Third Quarter 2007 6
... Humphrey Field Analyzer II-i series is a ... the patient's visual field. By using SitaTM, ... is reduced by up to 70%. A ... ergonomic design to increase patient comfort while ...
... Made Toric soft contact lenses let you enjoy ... soft toric lens in a lens custom made ... comfort is made possible by PC Technology™, which ... (PC), a substance found naturally in human cell ...
Frequency 55 Toric XR is a great option for those with high levels of astigmatism...
A low water content prism-ballasted toric soft lens manufactured using patented Toric Generating lathe-cutting technology and designed for use in the correction of astigmatism on a daily wear basis....
Medicine Products: